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Fast RNA conjugations on solid phase by strain-promoted cycloadditions†
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Strain promoted cycloaddition is presented as a tool for RNA conjugation on the solid phase;
RNA-cyclooctyne conjugates are prepared by cycloaddition to both azide (strain-promoted azide–alkyne
cycloaddition, SPAAC) and nitrile oxide dipoles (strain-promoted nitrile oxide–alkyne cycloaddition,
SPNOAC). The conjugation is compatible with 2′-OMe blocks and with 2′-O-TBDMS protection on the
ribose moieties of the sugar. Nitrile oxide dipoles are found to be more reactive click partners than azides.
The conjugation proceeds within 10 min in aqueous solvents, at room temperature without any metal
catalyst and tolerates dipoles of varying steric bulk and electronic demands, including pyrenyl, coumarin
and dabcyl derivatives.
Introduction
Currently, chemically-modified oligonucleotides are in high
demand due to their utility in diagnostic,1,2 therapeutic,3 nano-
technology4 and materials science applications.5 The most attrac-
tive reactions for the chemical transformation of nucleic acid
substrates are those which proceed in aqueous media at ambient
temperature and tolerate the presence of oxygen.
Although Cu(I)-catalysed azide–alkyne cycloaddition
(CuAAC) reactions are widely employed in synthetic chemistry,6
materials science,7 and in chemical biology8,9 the “click” con-
ditions required are not ideal for nucleic acid modification as
copper ions mediate Fenton-type DNA damage, leading to
strand breaks.8,10,11 Although the addition of stabilising ligands
can be effective in minimizing this degradation, the toxicity of
Cu(I) still remains potentially problematic.12 To overcome these
issues, several metal-free bio-conjugation chemistries have been
developed. We and others have reported the application of nitrile
oxide derivatives to the modification of nucleosides, oligo-
nucleotides and polymers bearing alkene/alkyne functions.13–19
Other metal-free strategies include Diels–Alder cycloadditions,20
photoinduceable cycloadditions of tetrazines or nitrile imines to
alkenes21,22 and strain-promoted azide–alkyne cycloaddition
(SPAAC) reactions.
The potential of SPAAC reactions for bio-conjugation was
first described by Bertozzi and co-workers in 200423 and
exploited the intrinsic ring strain of a cyclooctyne moiety. The
reactivity of the first generation of monocyclic octynes have sub-
sequently been ameliorated by incorporating a ring heteroatom,24
electron withdrawing substituents,20 or introducing further strain
by fusing two aromatic rings to the (aza)cyclooctyne core,25,26
SPAAC reactions have since found applications in bioima-
ging,24,27 peptide conjugation,28 drug delivery29 and surface and
materials science.30,31
We have previously reported post-synthetic modification of
DNA by strain-promoted cycloaddition of both azide and nitrile
oxide dipoles to solid-supported DNA-cyclooctyne sub-
strates.32,33 Filippov et al.,34 and Manoharan et al.,35 have
demonstrated azide-mediated oligonucleotide-dibenzocyclo-
octyne conjugation in solution phase, using the same metho-
dology as that described for DNA-templated “click”-ligation
demonstrated by Brown and El-Sagheer.36
As part of an ongoing programme to prepare siRNA conju-
gates with improved potential for cellular delivery, we became
interested in the possibility of RNA functionalization using
strain-promoted cycloaddition chemistry. In particular, we were
interested in solid-supported RNA substrates bearing monocyclic
octynes as handles for conjugation to a variety of ligands/labels.
The attractions of solid phase synthesis (SPS) include ease of
purification and the possibility to automate the ligation pro-
cedure. The choice of a non-substituted cyclooctyne dipolaro-
phile partner for the SPAAC reaction offers advantages in terms
of facile synthetic accessibility33 and reduced steric bulk and
lipophilicity leading to enhanced aqueous solubility with a
reduced tendency to give non-specific interactions with hydro-
phobic proteins.37 We wish to report here solid phase, post-
synthetic RNA conjugation by SPAAC and strain-promoted
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nitrile oxide–alkyne cycloaddition (SPNOAC) reactions as sum-
marised in Scheme 1.
Results and discussion
RNA substrates 1–5 were prepared using standard solid-phase
protocols prior to manual coupling of the cyclooctyne phosphor-
amidite 6 and subsequent oxidation of the terminal phosphite
triester (Scheme 2).33 Near quantitative conversion of 1–5 to the
putative solid-bound RNA-cyclooctynes (7–11) was indicated by
RP-HPLC and MALDI-TOF-MS analysis of the deprotected
oligonucleotide-cyclooctyne conjugates 12–16.
CPG-RNA cyclooctyne 7 and benzyl azide, 17, were selected
as model reactants with which to study solid-supported RNA
modification by a SPAAC reaction. The reaction was conducted
on a 0.1 μmol scale (supported oligonucleotide) with 20 equiva-
lents of azide in aqueous DMSO (50% v/v). The reaction was
complete within 30 min under ambient conditions (as evidenced
by RP-HPLC), and the putative support-bound conjugate 22a
was subsequently cleaved from the resin and deprotected to
afford the RNA conjugate 23a (Scheme 3, Table 1). HPLC
analysis showed formation of putative regioisomeric cyclo-
adducts; MALDI-TOF-MS data was consistent with the structure
of 23a. Similarly, 7 was conjugated with cinnamyl azide 1838 to
give regioisomeric products 23b in high yield (by HPLC).
Having established that the solid-supported RNA-cyclooctyne
dipolarophile 7 is a suitable substrate for SPAAC with simple
azide dipoles, the compatibility of the conditions with labels
bearing a range of functionalities was investigated. Thus, 7 was
treated with biotinyl-(19),32 cholesteryl-(20)32 or fluoresceinyl-
(21)32 azides in both aqueous and non-aqueous media at room
temperature. Conjugation to the biotinyl azide (19), furnished
23c after 4 h in 90% (v/v) aqueous DMSO, whilst DCM was the
solvent of choice for cholesteryl conjugation. The success of the
SPAAC to furnish lipid conjugates is suggestive of a future in
Scheme 1 Solid-supported RNA conjugation by strain-promoted
cycloaddition chemistry.
Scheme 3 SPAAC of RNA-cyclooctyne 7 to form conjugates 23a–e.
Scheme 2 Solid-supported synthesis of RNAs bearing cyclooctyne “click” partners.




























































drug formulation free from the inherent toxicity which plagues
cationic delivery vehicles.39,40 The fluorescein azide 21 was
selected to demonstrate the potential of SPAAC for introduction
of fluorescent tags. Having previously demonstrated that 21
required post-synthetic conjugation to DNA,32 the same strategy
was adopted for RNA-cyclooctyne 12. Thus, 12 (0.025 μmol,
1 eq., 200 μM), obtained from 7 following cleavage from the
resin and deprotection, was exposed to a solution of 21 (40 eq.)
in aqueous DMF. The reaction, as judged by HPLC, progressed
cleanly and was complete in 24 h at room temperature. The iden-
tity and integrity of the conjugate, which retained the yellow
colour characteristic of molecules incorporating a tetracyclic
fluorescein skeleton, as 23e was supported by MALDI-TOF
mass analysis (Table 2).
In formation of the conjugates 23a through d, it was observed
that as the steric bulk of the azide partner increased, from benzyl
through to cholesterol, the rate of conjugation decreased. Com-
monly reported strategies which enhance the rate of strain-
promoted cycloaddition reactions include the use of activated
cyclooctynes, e.g. dibenzocyclooctynes,25 and/or dipoles which
are more reactive than the azide, e.g. nitrile oxides. A flip side of
the enhanced reactivity of nitrile oxide dipoles is their potential
to partake in side reactions, e.g. dimerization, for this reason in
exploring the utility of SPNOAC reactions for conjugation
to support-bound oligonucleotides the dipoles were generated
in situ from stable precursor aryl aldoximes. Thus, a suspension
of 8 in 50% (v/v) aqueous ethanol was exposed to benzonitrile
oxide and reaction progress was followed by RP-HPLC. Conju-
gation was completed within 10 min at room temperature
(Fig. 1b) and the regioisomeric isoxazole-RNA conjugates 33a
were obtained in near quantitative yield following work-up,
deprotection and cleavage from the support, (Scheme 4).
The relative rates of the SPAAC and SPNOAC reactions
using cycloalkyne 8 were compared using phenyl azide and
Table 1 Structures of azides 17–21 and triazole conjugates 23a–e
Azide, R-N3 R Resin-supported conjugate Triazole-conjugate
17 PhCH2 22a 23a




Table 2 Conditions for SPAAC of azides 17–21 with support-bound
RNA-cyclooctyne, 7 and MALDI-TOF MS data
Azide Solvent Reaction time Product
MALDI-TOF MS
calculated, found
17 50% aq. DMSO 30 min 23a 6624, 6623
18 50% aq. DMSO 30 min 23b 6650, 6650
19 90% aq. DMSO 4 h 23c 6831, 6833
20 DCM 24 h 23d 7018, 7020
21a 90% aq. DMF 24 h 23e 6931, 6934
aReaction with fluoresceinyl azide 21 was conducted in solution.
Fig. 1 HPLC traces (recorded at 260 nm) of: (a) crude RNA-cyclooc-
tyne 13, resulting from deprotection and cleavage from the support 8;
and b–d) the crude reaction products resulting from reaction of the
RNA-cyclooctyne 8; (b) with phenyl nitrile oxide after 10 min showing
regioisomeric cycloadducts; (c) with phenyl azide after 10 min showing
no reaction; (d) phenyl azide for 18 h showing incomplete consumption
of starting RNA-cyclooctyne. HPLC analysis conditions A (for a and b)
or C (for c and d).




























































benzonitrile oxide, and the success of each reaction judged by
HPLC analysis of the crude reaction products (Fig. 1). Whilst
reaction with the nitrile oxide was complete in just 10 min at
room temperature, under the same conditions no conjugation
was observed with phenyl azide. In fact, even after 18 h reaction
time with the azide dipole, conjugation was still not complete
(Fig. 1d). The failure of HPLC to resolve the expected regio-
isomeric triazoles 23f (R = Ph) is not unprecedented.41
To demonstrate the scope of SPNOAC reactions, the oximes,
25–30,16,33,42,43 (Fig. 2), were selected as nitrile oxide precur-
sors. The analogous dipoles were generated immediately prior to
use following 10 min exposure of the parent oxime to a solution
of chloramine-T at room temperature. The choice of solvent was
dictated by the solubility of the oxime and product nitrile oxide
(Table 3). Thus, as with benzaldoxime, 25 26 and 27 were dis-
solved in aqueous EtOH and oxidised to the corresponding
nitrile oxides. Addition of the nitrile oxide solutions derived
from 25 and 26 to the solid-supported oligonucleotide-alkyne 8
and of the solutions derived from 25–27 to the solid-supported
cyclic alkyne 9, followed by agitation of the mixtures at room
temperature for 10 min gave near quantitative conversion to the
regioisomeric isoxazole-conjugates 33b–c and 34b–d, following
deprotection. The identity of these compounds was evidenced by
MALDI-TOF-MS analysis.
Pyrene-1-nitrile oxide, coumarin-6-nitrile oxide, and 4-(N,N-
dimethylamino)phenylazo-benzonitrile oxide, generated in situ,
from the corresponding oximes 28–30, were selected as building
blocks with potential to rapidly introduce reporter groups to
RNA substrates. DMF/ethanol was selected as the solvent
for dipole generation and cycloaddition, and RNA-8 as the
model substrate. In each case, HPLC analysis of the cleaved,
deprotected, but unpurified reaction products indicated complete
consumption of 8 within 10 min, and formation of regioisomeric
mixtures of RNA-conjugates 33d–f (Scheme 4). MALDI-TOF
MS data supported the structural integrity of the conjugates
33d–f.
No modification to the reaction conditions was required for
conjugation to longer oligonucleotides, and the support-bound
19-mer cyclooctyne 7 was converted, almost quantitatively, to
the regioisomeric RNA-isoxazole conjugates 38 whose structural
assignment was supported by MALDI-TOF-MS (Scheme 5,
Table 3). To illustrate the potential of the SPNOAC to deliver
“native” RNA conjugates, i.e. those bearing a free 2′-hydroxyl
group either as an alternate or gapmer, sequences 10 and 11 were
Scheme 4 SPNOAC of RNA-cyclooctynes 8 and 9 with a range of nitrile oxides.
Fig. 2 Oximes employed as nitrile oxide precursors in synthesis of
cycloadducts 33–34, 38–40.
Table 3 Conditions for SPNOAC cycloaddition to support bound











24 50% aq. EtOH 8 33a 1595, 1596
9 34a 3374, 3379
7 38 6607, 6611
10 39 2234, 2238
11 40 1958, 1960
25 50% aq. EtOH 8 33b 1613, 1614
9 34b 3392, 3393
26 50% aq. EtOH 8 33c 1645, 1647
9 34c 3424, 3428
27 50% aq. EtOH 9 34d 3434, 3436
28 DMF–EtOH 7 : 3 8 33d 1719, 1721
29 DMF–EtOH 7 : 3 8 33e 1688, 1684
30 DMF–EtOH 7 : 3 8 33f 1744, 1746




























































investigated. These sequences have some of the ribose sugars
bearing 2′-O-TBDMS protecting groups and others bearing
2′-OMe blocks; thus U6-cyclooctyne 10, has the alternate
pattern. The RNA-cyclooctyne 11, with 2′-OMe blocking groups
on the ribose units at each terminus and 2′-O-TBDMS protecting
groups on the central ribose moieties is defined as a gapmer.
Both sequences were tested as substrates in SPNOAC under the
standard conditions described above. In each case after 10 min
reaction at room temperature with benzonitrile oxide and follow-
ing work up, including cleavage from the support, and full
(base and sugar) deprotection, HPLC analysis revealed complete
conversion to the regioisomeric RNA-isoxazole conjugates 39
and 40 (Scheme 5). MALDI-TOF-MS supported the structural
integrity of all new conjugates (Table 3).
Conclusions
We have developed fast, strain promoted cycloaddition as a tool
for RNA conjugation on the solid phase exploiting the cyclo-
addition of a series of RNA-cyclooctynes with both azide
(SPAAC) and nitrile oxide dipoles (SPNOAC). The reaction is
compatible with 2′-OMe blocking as well as with 2′-O-TBDMS
protection on the ribose moieties of the sugar. Nitrile oxides are
found to be more reactive dipole partners than azides. The
copper free click conjugations proceed in aqueous solvents, in
10 min at room temperature under atmospheric conditions. The
successful ligation to monocyclic alkynes, with reduced steric
demands and hydrophobic character relative to diaryl fused ana-
logues, may be of benefit to those applications seeking enhanced
aqueous solubility. The SPNOAC reaction, which tolerates
dipoles of varying steric bulk and electronic demands, including
pyrenyl, coumarinyl and dabcyl provides complementarity to
recent reports on copper-promoted and copper free conjugation
of, ligase generated, “clickable” RNAs.44,45
Experimental section
General experimental
Mass analysis was performed on an Applied Biosystem Voyager
with 3-hydroxypicolinic acid or 2′,4′,6′-trihydroxyacetophenone
as matrix or recorded by Metabion, Germany. UV analysis was
performed on a Jasco V-630BIO spectrophotometer at 25 °C.
HPLC was carried out using either using a Gilson instrument
equipped with a diode array detector [Nucleosil C18 column
(4.6 × 250 mm, 5 μm) or Phenomenex C18 column (4.6 ×
250 mm, 5 μm)], or using a Dionex Ultimate 3000 instrument
equipped with a Clarity Oligo RP C18 (4.6 × 250 mm, 5 μm)
column. RNA monomers were purchased from Link Techno-
logies UK. Desalting of oligonucleotide samples was conducted
using illustra NAP-10 Sephadex G-25 DNA grade columns pur-
chased from GE Healthcare.
Synthesis of RNA substrates 1–5
Oligonucleotide syntheses were conducted on an Expedite 8909
DNA/RNA or ABI 394 synthesizer using commercially available
2′-OMe or 2′-O-TBDMS phosphoramidites, and followed stan-
dard RNA synthesis protocols.
General procedure for preparation of RNA-cyclooctynes 7–11
To manually couple the cyclooctyne phosphoramidite 633 to the
oligonucleotide, 500 μL of a 100 mM solution of the phosphor-
amidite in anhydrous CH3CN was added to the CPG-supported
oligonucleotide (1 μmol) along with 500 μL of a 0.3 M solution
of 5-benzylmercaptotetrazole in CH3CN. The mixture was
allowed to react for 15 min at room temperature with mixing
between syringes. This procedure was repeated with a second
portion of a fresh solution of phosphoramidite and 5-benzyl-
mercaptotetrazole. The CPG was washed with CH3CN (5 ×
2 mL), then exposed to oxidizer (700 μL, 0.1 M iodine solution
in THF–pyridine–water; 78 : 20 : 2). Following washing with
CH3CN (2 × 5 mL) the CPG-support was dried under vacuum
using a vacuum concentrator. Cleavage and base deprotection of
the cyclooctyne modified 2′-OMe blocked oligonucleotides 7–9,
and the alternate or gapmer substrates 10–11, from the support
proceeded by the method described below furnishing cyclo-
octyne-modified RNAs 12–16.
General procedure for oligonucleotide cleavage and deprotection
For analytical purposes a portion of each oligonucleotide was
cleaved from the CPG and protecting groups removed from the
base following incubation either in 40% (w/v) aqueous CH3NH2
(500 μL) at 65 °C for 15 min for substrates 12–16 (method i), or
in 28% (w/v) aqueous NH4OH (500 μL) at 25 °C for 30 min for
Scheme 5 SPNOAC of RNA-cyclooctynes 7, 10 and 11 with benzonitrile oxide.




























































substrates 33e-f (method ii). The CH3NH2/NH4OH was evapo-
rated using a concentrator. The CPG was washed with H2O
(4 × 200 μL aliquots), all solutions and washings were combined
to afford an aqueous solution of the oligonucleotide products
which were concentrated on a vacuum concentrator prior to
HPLC analysis.
Full deprotection of alternate and gapmer oligonucleotides
10–11 and 36–37
An aqueous sample of the oligonucleotide, cleaved from the
solid support and methylamine-deprotected as described above
was cooled on ice. The supernatant was decanted and set aside
and the support washed with EtOH–MeCN–H2O (1 : 1 : 3 (v/v/v)
3 × 150 μL). The supernatant and washings were combined and
evaporated to dryness. Removal of the TBDMS group was
effected following treatment with a solution of N-methylpyrroli-
done–triethylamine–triethylamine tris(hydrofluoride) (6 : 3 : 4
(v/v/v), 250 μL) at 65 °C for 1.5 h. The reaction mixture was
allowed to cool to room temperature and excess fluoride
quenched following addition of isopropyl trimethylsilylether
(500 μL) with periodic vigorous shaking over a 10 min period.
Diethyl ether (1 mL) was added and the mixture agitated vigo-
rously. Following centrifugation at 5000 rpm, the supernatant
was carefully removed and the residual solid pellet re-suspended
in triethylammonium acetate buffer (pH 7) (1 mL) before analy-
sis by RP-HPLC.
General methods for HPLC analysis
Cyclooctyne-modified oligonucleotides and click conjugation
products were analyzed by reverse-phase HPLC under either
conditions A (for products 12–16, 33a–d, 34a–d), conditions B
(for products 33e–f, 38–40), or conditions C (for products 23a–e).
Conditions A: 200 μL injection loop. Buffer A: 0.1 M TEAAc
(aq), pH 6.5; Buffer B: 0.1 M TEAAc, pH 6.5, 65% (v/v)
MeCN (aq). Gradient: 0–3 min, 5% B; 3–23 min, 5 → 95%
B. Flow rate: 1.0 mL min−1. Detection at 260 nm. Column:
Phenomenex C18 column (4.6 × 250 mm, 5 μm).
Conditions B: 20 μL injection loop. Buffer A: 0.1 M TEAAc,
pH 6.5, 5% (v/v) MeCN (aq); Buffer B: 0.1 M TEAAc, pH 6.5,
65% (v/v) MeCN (aq). Gradient; 0–5 min, 5% B; 5–20 min, 5
→ 95% B; 20–28 min, 95% B. Flow rate: 1.0 mL min−1. Detec-
tion at 260 nm. Column: Phenomenex Clarity Oligo C18
column, 5 μm.
Conditions C: 200 μL injection loop. Buffer A: 0.1 M TEAAc
(aq), pH 7.6; Buffer B: 0.1 M TEAAc, pH 7.6, 65% (v/v)
MeCN (aq). Gradient: 0–4.3 min, 5% B; 4.3–16.6 min,
5 → 100% B. Flow rate: 1.0 mL min−1. Detection at 260 nm.
Column: Phenomenex C18 column (4.6 × 250 mm, 5 μm)
Procedures for click conjugation by SPAAC on the solid phase
Preparation of conjugates 23a–c. To solid-supported
CPG-RNA-cyclooctyne 7 (0.12 μmol) in an Eppendorf tube was
added a solution of the azide (10 μL of a 240 mM stock solution
in DMSO, 2.4 μmol, 20 equivalents) and the volume was
adjusted to 20 μL with DMSO and water according to the
solubility of the azide (Table 1). The mixture was agitated at
room temperature. After completion of the conjugation
reaction (Table 1), the CPG was washed firstly with CH3CN
(5 × 300 μL) and then H2O (1 × 300 μL). In the case of the
biotin cycloadduct 23c, DMSO was used instead of CH3CN
during the work-up. Cleavage from the solid support, deprotec-
tion (method i) and HPLC analysis (conditions C) were followed
by the procedures described above to give 23a–c.
Preparation of cholesterol conjugate, 23d. To solid supported
CPG-RNA-cyclooctyne 7 (0.12 μmol) in an Eppendorf tube was
added a solution of the cholesteryl azide 20 (20 μL of a 240 mM
stock solution in DCM, 2.4 μmol, 20 equivalents) and the result-
ing mixture was agitated at room temperature for 20 h.
After completion of the conjugation reaction, the CPG was
washed with DCM (5 × 300 μL), CH3CN (1 × 300 μL) and H2O
(1 × 300 μL). Cleavage from the support, deprotection (method
i) and HPLC analysis (conditions C) were followed by the pro-
cedures described above to give 23d.
Preparation of fluorescein conjugate, 23e in solution phase.
Following deprotection and cleavage from the solid support
(method i), a solution of RNA-cyclooctyne 12 (125 μL, 200 μM,
0.025 μmol) was evaporated to dryness. To this was added a
solution of the fluorescein azide 21 (9.0 μL of a 112 mM stock
solution in DMF, 1.0 μmol, 40 equivalents) and H2O (0.5 μL).
The resulting solution was agitated for 24 h at room temperature.
H2O (200 μL) was added and this solution was washed with
EtOAc (10 × 300 μL) to remove the excess azide. Any remaining
EtOAc was removed under vacuum and the resulting aqueous
solution was analysed and purified by reversed-phase HPLC
(conditions C) to furnish 23e.
Procedures for click conjugation by SPNOAC on the solid phase
To a suspension of solid supported oligonucleotide-cyclooctynes
7–11 (0.2 μmol) in an Eppendorf tube in 100 μL of the appro-
priate solvent (Table 2) was added 10 μL of a premixed solution
of the oxime (3.3 μmol) and chloramine-T monohydrate
(3.3 μmol) in the stated solvent (Table 2). The combined mixture
was agitated at room temperature for 10 min. Following settling
the supernatant liquid was removed by syringe and the CPG
Table 4 Washing solvents selected for work-up of isoxazole
conjugates
Product(s) Washing solvents
33a, 34a CH3CN (5 × 300 μL), CH3OH (3 × 200 μL) H2O
(4 × 300 μL).38, 39, 40
33b, 34b CH3CN (5 × 300 μL), CH3OH (3 × 200 μL) H2O
(4 × 300 μL).
33c, 34c CH3CN (5 × 300 μL), CH3OH (3 × 200 μL) H2O
(4 × 300 μL).
34d CH3CN (5 × 300 μL), CH3OH (3 × 200 μL) H2O
(4 × 300 μL).
33d DMF (5 × 300 μL), CH3OH (3 × 200 μL) H2O
(4 × 300 μL).
33e DMF (5 × 300 μL), CH3OH (3 × 200 μL) H2O
(4 × 300 μL).
33f DMF (5 × 300 μL), CH3OH (3 × 200 μL) H2O
(4 × 300 μL).




























































washed as outlined in the Table 4 below. Cleavage from the solid
support, deprotection (method i) and HPLC analysis (conditions
A and B) were followed by the procedures described above.
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